BioCentury | Feb 14, 2011
Clinical News

Staphylokinase: Phase III started

...Bharat began an open-label, Indian Phase III trial to compare a 30 mL double-bolus of staphylokinase...
...about 120 AMI patients. Bharat has an exclusive license from ThromboGenics to develop and commercialize THR-100...
...Product: Staphylokinase ( THR-100 ) (formerly Sak42D ) Business: Cardiovascular Molecular target: NA Description: Recombinant staphylokinase...
BioCentury | Jul 10, 2008
Cover Story

Marrying Activase with Gleevec

...models to study the efficacy of imatinib in combination with other thrombolytics, including urokinase, streptokinase, staphylokinase...
BioCentury | May 19, 2008
Clinical News

THR-100: Phase III start

...an Indian Phase III trial. ThromboGenics granted Bharat an exclusive license to develop and commercialize THR-100...
...India ThromboGenics N.V. (Euronext:THR), Leuven, Belgium Product: THR-100 Business: Cardiovascular Molecular target: NA Description: Recombinant staphylokinase...
BioCentury | Oct 8, 2007
Company News

Minapharm Pharmaceuticals S.A.E., ThromboGenics deal

...will receive an undisclosed upfront payment and is eligible for milestones and double-digit royalties. The staphylokinase...
BioCentury | Dec 18, 2006
Finance

Ebb & Flow

...the announcement that it was granting India's Bharat Biotech a license to its recombinant staphylokinase THR-100...
BioCentury | Dec 11, 2006
Company News

ThromboGenics, Bharat Biotech deal

...THR granted Bharat an exclusive license to develop and commercialize THR-100 to treat acute myocardial infarction...
...eligible for double-digit royalties. THR has completed a European Phase II trial of the recombinant staphylokinase...
BioCentury | Jun 12, 2006
Strategy

Back in the limelight

...Collen, whose laboratory was the first to produce t-PA for clinical use, thinks the company's staphylokinase...
...microplasmin , is a direct-acting thrombolytic in Phase II studies. "The first experiments suggesting that staphylokinase...
...1991, Collen and colleagues at the Katholieke Universiteit Leuven spun out Thromb-X N.V. to develop staphylokinase...
BioCentury | Jun 11, 2001
Finance

Cardio space

...ThromboGenics PEG-Sak pegylated mutant staphylokinase protein Ph IIb Acute myocardial infarction (heart attack) Private SY162 staphylokinase...
BioCentury | Apr 23, 2001
Clinical News

SY162: Began Phase II testing

...ThromboGenics Ltd., Dublin, Ireland Product: SY162 Business: Cardiovascular Therapeutic category: Thrombolysis/Thrombosis Target: Fibrin Description: Staphylokinase variant...
BioCentury | Apr 23, 2001
Clinical News

SY162: Began Phase II testing

...ThromboGenics Ltd., Dublin, Ireland Product: SY162 Business: Cardiovascular Therapeutic category: Thrombolysis/Thrombosis Target: Fibrin Description: Staphylokinase variant...
Items per page:
1 - 10 of 11